{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:45:14Z","timestamp":1778589914919,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":893,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1038\/s41379-020-0504-5","type":"journal-article","created":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T11:03:42Z","timestamp":1583924622000},"page":"1546-1556","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Integrated genomic characterization of ERBB2\/HER2 alterations in invasive breast carcinoma: a focus on unusual FISH groups"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1051-502X","authenticated-orcid":false,"given":"Soo-Ryum","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosr","family":"Bouhlal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco M.","family":"De La Vega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan","family":"Ballard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Calvin J.","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Vilborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Allison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/s41379-020-0504-5_bib1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1038\/s41379-020-0504-5_bib2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.clbc.2014.11.009","article-title":"Current HER2 testing recommendations and clinical relevance as a predictor of response to targeted therapy","volume":"15","author":"Ballinger","year":"2015","journal-title":"Clin Breast Cancer"},{"key":"10.1038\/s41379-020-0504-5_bib3","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1200\/JCO.1997.15.8.2894","article-title":"HER-2\/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas","volume":"15","author":"Press","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-0504-5_bib4","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1038\/s41379-020-0504-5_bib5","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-0504-5_bib6","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1200\/JCO.2011.35.0868","article-title":"Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31","volume":"29","author":"Perez","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-0504-5_bib7","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1200\/JCO.2016.66.6693","article-title":"HER2 gene amplification testing by fluorescent in situ hybridization (FISH): comparison of the ASCO-College of American Pathologists guidelines with FISH scores used for enrollment in Breast Cancer International Research Group clinical trials","volume":"34","author":"Press","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-0504-5_bib8","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1001\/jamaoncol.2018.6012","article-title":"Assessment of ERBB2\/HER2 status in HER2-equivocal breast cancers by FISH and 2013\/2014 ASCO-CAP guidelines","volume":"5","author":"Press","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1038\/s41379-020-0504-5_bib9","doi-asserted-by":"crossref","first-page":"8604","DOI":"10.1021\/ac202028g","article-title":"High-throughput droplet digital PCR system for absolute quantitation of DNA copy number","volume":"83","author":"Hindson","year":"2011","journal-title":"Anal Chem"},{"key":"10.1038\/s41379-020-0504-5_bib10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41571-018-0002-6","article-title":"The emerging clinical relevance of genomics in cancer medicine","volume":"15","author":"Berger","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1038\/s41379-020-0504-5_bib11","doi-asserted-by":"crossref","unstructured":"Rowlands V, Rutkowski AJ, Meuser E, Carr TH, Harrington EA, Barrett JC. Optimisation of robust singleplex and multiplex droplet digital PCR assays for high confidence mutation detection in circulating tumour DNA. Sci Rep. 2019;9. https:\/\/doi.org\/10.1038\/s41598-019-49043-x.","DOI":"10.1038\/s41598-019-49043-x"},{"key":"10.1038\/s41379-020-0504-5_bib12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10549-019-05425-3","article-title":"Multiplex ddPCR assay for screening copy number variations in BRCA1 gene","volume":"178","author":"Oscorbin","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1038\/s41379-020-0504-5_bib13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10549-016-4092-5","article-title":"Use of droplet digital PCR for quantitative and automatic analysis of the HER2 status in breast cancer patients","volume":"162","author":"Otsuji","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1038\/s41379-020-0504-5_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/s41525-017-0041-4","article-title":"A robust targeted sequencing approach for low input and variable quality DNA from clinical samples","volume":"3","author":"So","year":"2018","journal-title":"npj Genom Med"},{"key":"10.1038\/s41379-020-0504-5_bib15","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/bib\/bbs017","article-title":"Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration","volume":"14","author":"Thorvaldsdottir","year":"2013","journal-title":"Brief Bioinform"},{"key":"10.1038\/s41379-020-0504-5_bib16","doi-asserted-by":"crossref","first-page":"2005.0008","DOI":"10.1038\/msb4100012","article-title":"Phosphotyrosine interactome of the ErbB-receptor kinase family","volume":"1","author":"Schulze","year":"2005","journal-title":"Mol Syst Biol"},{"key":"10.1038\/s41379-020-0504-5_bib17","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1126\/science.2999974","article-title":"Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene","volume":"230","author":"Coussens","year":"1985","journal-title":"Science"},{"key":"10.1038\/s41379-020-0504-5_bib18","doi-asserted-by":"crossref","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2. http:\/\/cancerdiscovery.aacrjournals.org\/content\/2\/5\/401.","DOI":"10.1158\/2159-8290.CD-12-0095"},{"key":"10.1038\/s41379-020-0504-5_bib19","doi-asserted-by":"crossref","first-page":"l1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"10.1038\/s41379-020-0504-5_bib20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nbt.3391","article-title":"Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity","volume":"34","author":"Chang","year":"2016","journal-title":"Nat Biotechnol"},{"key":"10.1038\/s41379-020-0504-5_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: a precision oncology knowledge base","volume":"1","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1038\/s41379-020-0504-5_bib22","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1158\/2159-8290.CD-12-0349","article-title":"Activating HER2 mutations in HER2 gene amplification negative breast cancer","volume":"3","author":"Bose","year":"2013","journal-title":"Cancer Disco"},{"key":"10.1038\/s41379-020-0504-5_bib23","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature25475","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature"},{"key":"10.1038\/s41379-020-0504-5_bib24","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/modpathol.2015.112","article-title":"Impact of updated HER2 testing guidelines in breast cancer\u2014re-evaluation of HERA trial fluorescence in situ hybridization data","volume":"28","author":"Stoss","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-020-0504-5_bib25","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/modpathol.2016.175","article-title":"\u2018Non-classical\u2019 HER2 FISH results in breast cancer: a multi-institutional study","volume":"30","author":"Ballard","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-020-0504-5_bib26","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1200\/JCO.2008.19.7939","article-title":"Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA trial","volume":"27","author":"Dowsett","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-0504-5_bib27","doi-asserted-by":"crossref","first-page":"6404","DOI":"10.1158\/1078-0432.CCR-06-3022","article-title":"Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification","volume":"13","author":"Arnould","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1038\/s41379-020-0504-5_bib28","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3346\/jkms.2009.24.5.910","article-title":"Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2\/neu amplification as a predictive factor for efficacy","volume":"24","author":"Han","year":"2009","journal-title":"J Korean Med Sci"},{"key":"10.1038\/s41379-020-0504-5_bib29","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/labinvest.2008.19","article-title":"Genomic analysis of the HER2\/TOP2A amplicon in breast cancer and breast cancer cell lines","volume":"88","author":"Arriola","year":"2008","journal-title":"Lab Investig"},{"key":"10.1038\/s41379-020-0504-5_bib30","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.molonc.2012.10.012","article-title":"The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells","volume":"7","author":"Sahlberg","year":"2013","journal-title":"Mol Oncol"},{"key":"10.1038\/s41379-020-0504-5_bib31","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.bbcan.2013.04.004","article-title":"The HER2 amplicon in breast cancer: topoisomerase IIA and beyond","volume":"1836","author":"Jacot","year":"2013","journal-title":"Biochim Biophys Acta\u2014Rev Cancer"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41379-020-0504-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41379-020-0504-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222007979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222007979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41379-020-0504-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:41:35Z","timestamp":1760229695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222007979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0893395222007979"],"URL":"https:\/\/doi.org\/10.1038\/s41379-020-0504-5","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrated genomic characterization of ERBB2\/HER2 alterations in invasive breast carcinoma: a focus on unusual FISH groups","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41379-020-0504-5","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}